Denovicon seamlessly integrates AI, machine learning, and molecular modeling approaches (such as quantum chemistry, molecular dynamics, and free-energy methods) into its (hybrid) computational drug discovery platform. With it, a vast amount of chemical space (~10²⁷ molecules) is quickly and accurately triaged, with only the most desirable analogs being identified as hits that are then ultimately transformed into clinical candidates. We are currently focused on small-molecule therapies for oncology and immuno-oncology targets.